Total
0
Shares
Actinogen Medical (ASX:ACW) - Chairman Geoff Brooke (middle) & CEO, Dr Bill Ketelbey (right) - The Market Herald
Chairman Geoff Brooke (middle) & CEO, Dr Bill Ketelbey (right)
Source: Actinogen Medical
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Actinogen Medical (ACW) is set to expand its intellectual property portfolio with two new patents
  • The healthcare stock filed the applications for its lead drug candidate, an Alzheimer's treatment known as Xanamen
  • Positively, the new submissions could extend the drug's patent life protection up to 2040
  • ACW's first patent covers a process which seeks to improve cognitive function or treat cognitive decline in healthy adults
  • Meanwhile, the second patent will protect Actinogen's scale-up manufacturing process
  • Looking ahead, Actinogen says it will continue to grow its patent portfolio and pursue opportunities to further advance its Xanamen treatment
  • Actinogen closed steady following today's news, with shares worth 2.2 cents each

Actinogen Medical (ACW) is set to expand its intellectual property portfolio with two new patents.

The healthcare stock filed the applications for its lead drug candidate, an Alzheimer's treatment known as Xanamen. Positively, the new submissions could extend the drug's patent life protection up to 2040.

ACW's first patent covers a process which seeks to improve cognitive function or treat cognitive decline in healthy adults. The company opted to pursue a patent based on a phase one clinical trial, which indicated Xanamen could improve cognitive function compared to a placebo in elderly patients.

The second patent will protect Actinogen's scale-up manufacturing process. It comes after the company worked with chemists and a Swiss-based contract development and manufacturing organisation (CDMO).

“Strengthening our IP portfolio and extending the patent life of protection over Xanamem is aligned with our broader commercialisation strategy," Actinogen CEO and Managing Director Dr Bill Ketelbey said.

"The potential to treat cognitively healthy subjects ... as well as treat those at risk of cognitive impairment, is a significant medical and commercial opportunity," he continued.

"Actinogen remains focused on maintaining and extending the protection of Xanamem to maximise its commercial potential," the CEO concluded.

Looking ahead, Actinogen says it will continue to grow its patent portfolio and pursue opportunities to further advance its Xanamen treatment.

Actinogen closed steady following today's news, with shares worth 2.2 cents each.

ACW by the numbers
More From The Market Herald
Pacific Smiles (ASX:PSQ) raises $15M for dental centre rollout

" Pacific Smiles (ASX:PSQ) raises $15M for dental centre rollout

Dental centre operator Pacific Smiles (PSQ) has successfully completed its $15 million placement.
MGC Pharmaceuticals (ASX:MXC) - Co Founder and Managing Director, Roby Zomer - The Market Herald

" MGC Pharmaceuticals (ASX:MXC) receives boosted ArtemiC order from SPC

MGC Pharmaceuticals (MXC) has received a significantly increased order from Swiss PharmaCan (SPC) for its ArtemiC Rescue product line.
Orthocell (ASX:OCC) - Managing Director, Paul Anderson - The Market Herald

" Orthocell (ASX:OCC) granted inclusion on Australian Prostheses List

Regenerative medicine company Orthocell (OCC) has been granted inclusion on the Australian Prostheses List.
Palla Pharma (ASX:PAL) raises $12.2M to improve working capital

" Palla Pharma (ASX:PAL) raises $12.2M to improve working capital

Pharmaceutical company Palla Pharma (PAL) has raised roughly $12.24 million via a placement and institutional entitlement offer.